GSK reports 76 percent complete responses as GSK stock trades at EUR 22.65
Published on 10/25/2026 at 17:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOncology update and dates
- Interim AZUR-1 results showed a 76 percent complete response rate on October 24, 2026.
- GSK stock traded at EUR 22.65 at 5:33 p.m. CEST at Lang & Schwarz on October 25, 2026.
- GSK presentations at ESMO continue on October 26, 2026.
GSK reported that 76 percent of evaluable patients achieved a complete response in the AZUR-1 trial on October 24, 2026, according to the GSK release. GSK stock traded at EUR 22.65 at 5:33 p.m. CEST in weekend trading at Lang & Schwarz on October 25, 2026.
GSK said the exploratory analysis covered 144 evaluable patients, with 110 achieving a complete response. The company also reported that 68 percent, or 98 of 144 patients, achieved a sustained clinical complete response for at least 12 months without surgery, based on investigator assessment.
Weekend trading
The Lang & Schwarz price was EUR 22.65 at 5:33 p.m. CEST on October 25, 2026. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of GSK stock.
Upcoming ESMO presentations
GSK's previously announced ESMO program includes further presentations on October 26, 2026, including studies involving risvutatug rezetecan, mocertatug rezetecan and dostarlimab. The company said the congress program includes more than 20 abstracts from its solid tumor portfolio, as detailed in its October 16 release.
Market context: Market report FTSE 100.
